Sonoma Pharmaceuticals, Inc. (SNOA) Financial Statements (2024 and earlier)

Company Profile

Business Address 5445 CONESTOGA COURT, SUITE 150
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
3/31/2023
12/31/2022
MRQ
3/31/2022
3/31/2021
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,8202,6347,3964,2203,6913,689
Cash and cash equivalents3,8202,6347,3964,2203,6913,689
Receivables2,5722,2972,4072,8064,0623,481
Inventory, net of allowances, customer advances and progress billings2,8582,8492,6632,5302,1923,409
Inventory2,8582,8492,6632,5302,1923,409
Prepaid expense 4,308 3,7463,2182,2561,616
Other undisclosed current assets2403,452218209182301
Total current assets:13,79811,23216,43012,98312,38312,496
Noncurrent Assets
Operating lease, right-of-use asset418471559769963
Property, plant and equipment488314320360365727
Deferred income tax assets9491,089829  
Other noncurrent assets733087711264122
Other undisclosed noncurrent assets5055146307637861,103
Total noncurrent assets:2,4332,6962,4152,0042,1781,952
TOTAL ASSETS:16,23113,92818,84514,98714,56114,448
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,8701,3024,5432,9233,8602,756
Employee-related liabilities1,0597871,078957
Accounts payable8411,3021,6411,7692,0861,255
Accrued liabilities 2,029 1,843367696544
Deferred revenue1001001,223267228
Debt431 808596481463
Other liabilities      270
Other undisclosed current liabilities3162,532(755)292296102
Total current liabilities:3,7173,9345,8194,0784,8653,591
Noncurrent Liabilities
Long-term debt and lease obligation  153091,83974612
Long-term debt, excluding current maturities  15 1,310 12
Liabilities, other than long-term debt302323182229245 
Deferred revenue140128182229245
Operating lease, liability162195309529746
Other undisclosed noncurrent liabilities4,2354,0973,8383,478 356
Total noncurrent liabilities:4,5374,4354,3295,546991368
Total liabilities:8,2548,36910,1489,6245,8563,959
Equity
Equity, attributable to parent7,9775,5598,6975,3638,70510,489
Common stock522222
Additional paid in capital200,904197,939197,370189,217186,559184,074
Accumulated other comprehensive loss(3,418)(4,176)(4,312)(4,579)(5,610)(4,349)
Accumulated deficit(189,514)(188,206)(184,363)(179,277)(172,246)(169,238)
Total equity:7,9775,5598,6975,3638,70510,489
TOTAL LIABILITIES AND EQUITY:16,23113,92818,84514,98714,56114,448

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Other undisclosed loss before gain (loss) on sale of properties(893)  
Revenues13,2726,41412,62818,62918,93618,970
Cost of revenue(8,795)(5,561)(8,635)(12,070)(10,603)(10,090)
Cost of goods and services sold(8,795)(5,561)(8,635)(12,070)(10,603)(231)
Gross profit:4,4778533,9936,5598,3338,880
Operating expenses(9,047)(9,525)(9,880)(10,008)(15,004)(20,138)
Operating loss:(4,570)(8,672)(5,887)(3,449)(6,671)(11,258)
Nonoperating income
(Investment Income, Nonoperating)
    1650190
Interest and debt expense  735723(12)(16)(33)
Other undisclosed loss from continuing operations before equity method investments, income taxes  (14)    
Loss from continuing operations before equity method investments, income taxes:(4,570)(7,951)(5,164)(3,445)(6,637)(11,101)
Other undisclosed income (loss) from continuing operations before income taxes(614)(578)(254)(457)3,812(239)
Loss from continuing operations before income taxes:(5,184)(8,529)(5,418)(3,902)(2,825)(11,340)
Income tax expense (benefit)33(99)332(713)(121)(458)
Other undisclosed income (loss) from continuing operations 882    
Loss from continuing operations:(5,151)(7,746)(5,086)(4,615)(2,946)(11,798)
Loss before gain (loss) on sale of properties:(6,700)(5,086)(3,950)(2,946)(11,798)
Income from discontinued operations    665  
Other undisclosed net loss(31)(313)(313)   
Net loss:(5,182)(8,952)(5,399)(3,950)(2,946)(11,798)
Other undisclosed net income attributable to parent31313313   
Net loss available to common stockholders, diluted:(5,151)(8,639)(5,086)(3,950)(2,946)(11,798)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
3/31/2023
12/31/2022
TTM
3/31/2022
3/31/2021
3/31/2020
3/31/2019
Net loss:(5,182)(8,952)(5,399)(3,950)(2,946)(11,798)
Other comprehensive loss    (2,919)(4,207)(12,172)
Other undisclosed comprehensive income925716580   
Comprehensive loss:(4,257)(8,236)(4,819)(6,869)(7,153)(23,970)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (1,375)    
Comprehensive loss, net of tax, attributable to parent:(4,257)(9,611)(4,819)(6,869)(7,153)(23,970)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: